Comparing odronextamab to standard chemo for untreated follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests if a new drug called odronextamab is safe and works as well as a common antibody (rituximab) plus chemotherapy for people with a type of slow-growing lymphoma that hasn't been treated yet. It's for adults with grade 1-3a follicular lymphoma that is bulky stage II or stage III/IV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called follicular lymphoma, grades 1 to 3a, that is stage II bulky or stage III/IV
- Your lymphoma should not have received any previous treatment to fight it throughout your body
- You must have at least one tumor that can be seen on a CT or MRI scan
- You need to be well enough to do daily activities (ECOG performance status 0-2)
- Your bone marrow and liver must be working adequately based on blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three targeted drugs (Orelabrutinib, Obinutuzumab, and Lenalidomide) against the standard approach for people with follicular lymphoma who haven't been treated yet. The goal is to see if the new drug combo works better and is safe.
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
This trial tests a new immunotherapy drug, odronextamab, for people with slow-growing follicular lymphoma that hasn't been treated yet and isn't causing big problems. It aims to see if the drug can control the cancer with fewer side effects.
This trial tests whether a new drug, odronextamab, combined with lenalidomide works better than the current standard, rituximab combined with lenalidomide, for people whose follicular or marginal zone lymphoma has come back or not responded to prior treatment. It aims to see which combo is safer and more effective.
This study tests a new combination of two drugs (mosunetuzumab and lenalidomide) compared to standard chemo-immunotherapy for people with newly diagnosed follicular lymphoma that needs treatment. It aims to see if the new combination works better and has fewer side effects.
This Phase 1 trial tests whether a new medicine (REGN5837) given with odronextamab is safe in adults with aggressive B-cell non-Hodgkin lymphoma. It may help researchers learn if this combination can work for patients whose disease has progressed after earlier treatments.
Hear when a new Follicular Lymphoma (FL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.